The Best of 2012: Regeneron Pharmaceuticals

It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'll be reading through the naughty and nice lists (we've already checked them twice), counting down the 25 best-performing stocks and the 25 worst-performing stocks in the health care sector this year.

In this segment, Motley Fool health care analyst Max Macaluso takes a look at No. 14 on the nice list, Regeneron Pharmaceuticals (NASDAQ: REGN  ) , and how this company left investors with more than a little something extra in their stockings this year.

While looking at 2012 performance is useful, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 13, 2012, at 10:46 PM, stockman1948 wrote:

    ********ATTENTION ARNA INVESTORS*********

    What you are seeing below is taken direct from the most recent conference held by ARNA at NYC. This is an actual account of $$$ received and what is expected on announcement of the DEA scheduling. I suggest that you open and view what was said by ARNA executives and read the facts for yourself.

    • $55M in upfront payments received

    • $20M milestone payment received – FDA-approved prescribing information includes efficacy & safety data from BLOOM-DM

    • $65M following DEA scheduling

    • Eligible to receive up to an additional $54.5M in regulatory & development milestone payments


    This is an incredible amount of dollars that ARNA has earned and is projected to receive on the DEA scheduling and this is why many investors are confident that ARNA stock will skyrocket.


    STOKMAN 1948

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2152845, ~/Articles/ArticleHandler.aspx, 5/25/2016 1:23:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Max Macaluso

Max is the Technology, Biopharma & Health Care Bureau Chief at Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Today's Market

updated Moments ago Sponsored by:
DOW 17,875.92 169.87 0.96%
S&P 500 2,092.78 16.72 0.81%
NASD 4,903.69 42.64 0.88%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2016 1:06 PM
REGN $395.98 Down -1.72 -0.43%
Regeneron Pharmace… CAPS Rating: ***
DNDNQ $0.03 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
VVUS $1.26 Up +0.03 +2.44%
VIVUS, Inc. CAPS Rating: **